内科重症监护病房中的噬血细胞性淋巴组织细胞增生症:单中心队列研究聚焦急性肝衰竭与病死率
该单中心回顾性观察研究纳入2012年1月至2018年12月某三级医院内科ICU收治的31例危重噬血细胞性淋巴组织细胞增生症(HLH)患者。入院时常见体质性症状、肝酶升高和血小板减少。队列平均年龄48.1岁,45%为男性;28天病死率65%,1年病死率77%。28天存活者较未存活者更年轻、APACHE II评分更低(16.5 vs 23.0;p=0.004)、HScore更高(249.1 vs 226.0;p=0.032),且更少接受机械通气、肾脏替代治疗或血管升压药支持,更常接受HLH特异性化疗。29%的患者诊断为急性肝衰竭,其中仅22%在住院早期发生急性肝衰竭;急性肝衰竭与入院时更高的MELD评分相关。
要点
- 内科ICU危重HLH患者28天病死率65%、1年病死率77%(31例,2012–2018年单中心)。
- 28天存活者APACHE II评分低于未存活者(16.5 vs 23.0;p=0.004),HScore高于未存活者(249.1 vs 226.0;p=0.032)。
- 存活者更少接受机械通气、肾脏替代治疗或血管升压药支持,更常接受HLH特异性化疗。
- 该ICU队列中29%诊断为急性肝衰竭,其中仅22%在住院早期发生;急性肝衰竭与入院时更高MELD评分相关。
适用人群与场景
- 某三级医院内科ICU于2012年1月至2018年12月收治的31例危重噬血细胞性淋巴组织细胞增生症患者。
- 队列平均年龄48.1岁,45%为男性。
研究设计与关键结果
- 研究类型为回顾性观察研究,单中心,纳入31例危重HLH患者,无干预。
- 28天病死率65%,1年病死率77%。
- 28天存活者较未存活者更年轻,平均APACHE II评分更低(16.5 vs 23.0;p=0.004),平均HScore更高(249.1 vs 226.0;p=0.032)。
- 存活者更少接受机械通气、肾脏替代治疗或血管升压药支持,更常接受HLH特异性化疗。
- 29%的患者诊断为急性肝衰竭,其中仅22%在住院早期发生急性肝衰竭;急性肝衰竭与入院时更高的MELD评分相关。
- 发生急性肝衰竭者的可用组织学显示大片肝坏死,或组织细胞或淋巴细胞浸润。
- 入院时常见体质性症状、肝酶升高和血小板减少。
证据类型、等级与局限
- 证据类型:单中心回顾性观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,内科ICU的HLH患者病死率高;存活者APACHE II评分更低、HScore更高、更可能接受HLH特异性化疗且更少发生器官衰竭。
- 作者认为,HLH可与急性肝衰竭相关,尤其当入院时MELD评分升高时。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: Hemophagocytic lymphohistiocytosis is a life-threatening hyperinflammatory disorder that is associated with high morbidity and mortality in the ICU. It has also been associated with acute liver failure.
DESIGN: Retrospective observational study.
SETTING: Tertiary-care medical ICU.
PATIENTS: Thirty-one patients critically ill with hemophagocytic lymphohistiocytosis.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: We performed a comprehensive review of critically ill hemophagocytic lymphohistiocytosis patients admitted to a tertiary-care medical ICU from January 2012 to December 2018. Most patients presented with constitutional symptoms and elevated liver enzymes and thrombocytopenia were common upon hospital admission. ICU admission laboratory and clinical variables were used to calculate Acute Physiology and Chronic Health Evaluation II, hemophagocytic syndrome diagnostic score, and model for end-stage liver disease. Mean age of the cohort was 48.1 years, and 45% were male. The mortality rate was 65% at 28 days and 77% at 1 year. About 28-day survivors were younger, had lower mean Acute Physiology and Chronic Health Evaluation II score (16.5 vs 23.0; p = 0.004), and higher mean hemophagocytic syndrome diagnostic score (249.1 vs 226.0; p = 0.032) compared with nonsurvivors. Survivors were less likely to receive mechanical ventilation, renal replacement therapy, or vasopressor support and were more likely to receive chemotherapy for hemophagocytic lymphohistiocytosis. In this ICU cohort, 29% were diagnosed with acute liver failure, of whom only 22% developed acute liver failure early during their hospital stay. Acute liver failure was associated with a higher model for end-stage liver disease score upon hospital admission. Available histology in those that developed acute liver failure showed massive hepatic necrosis, or histiocytic or lymphocytic infiltrates.
CONCLUSIONS: Patients admitted to the ICU with hemophagocytic lymphohistiocytosis have a high mortality. Those who survived had lower Acute Physiology and Chronic Health Evaluation scores, had higher hemophagocytic syndrome diagnostic scores, are more likely to receive hemophagocytic lymphohistiocytosis specific chemotherapy, and are less likely to have organ failure. Hemophagocytic lymphohistiocytosis can be associated with acute liver failure especially when model for end-stage liver disease score is elevated upon admission.
参考来源
- Al Nasrallah N, Al-Hader A, Samala N, et al. Hemophagocytic Lymphohistiocytosis in the Medical ICU: A Single-Institution Cohort Study on Acute Liver Failure and Mortality. Crit Care Explor. 2021. PMID: 33458685. doi:10.1097/CCE.0000000000000318
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。